Tayure Progesterone Injection

Adult administration

1. Amenorrhea: Administer 25mg intramuscularly three times a week as progesterone during the last 2 weeks of the menstrual cycle. 2. Dysmenorrhea, premenstrual syndrome: Administer 10-25mg intramuscularly daily as progesterone for one week before menstruation starts. 3. Functional uterine bleeding: Administer 5-10mg intramuscularly daily as progesterone for 5 days until 2 days before the expected menstrual date. 4. Threatened abortion: Administer 10-50mg intramuscularly one to two times a day as progesterone. 5. Habitual abortion: Administer 5-20mg intramuscularly three times a week as progesterone from the early stages of pregnancy. 6. Infertility due to luteal phase deficiency: Administer 10-50mg intramuscularly one to two times a day as progesterone.

This medication contains benzyl alcohol, which can cause fatal respiratory problems in premature infants, so caution is advised. This medication should not be administered to certain patients. For example, patients allergic to this medication, those with renal disease, breast cancer, a history of thrombotic diseases, severe liver dysfunction, women who are pregnant or may become pregnant, as well as newborns or premature infants should not use it. Patients with asthma, migraine, epilepsy, heart or kidney diseases, or such history should be administered this medication with care. Caution is also required for patients with a history of depression, diabetes, slightly impaired liver function, hypertension, or photosensitivity. Various side effects such as urinary and genital bleeding, breast changes, skin rash, liver function abnormalities, gastrointestinal symptoms, central nervous system symptoms, vision problems, and local reactions can occur with this medication. If any of these symptoms arise, immediate consultation with medical personnel is required. It is important to undergo cervical cytology tests and breast and pelvic examinations every 6 months if this medication is used for a long time. If sudden vision abnormalities or migraines occur, the medication should be discontinued immediately, and a specialist should be consulted. This medication should only be administered after confirming pregnancy status, and regular checks should be conducted even when used to maintain pregnancy. This medication may interact with other drugs, so caution is especially needed for patients taking bromocriptine or cyclosporine. Safety during pregnancy has not been established; hence, women who may become pregnant or breastfeeding are advised not to use this medication. It is also not recommended for breastfeeding women as it can be excreted in breast milk. No specific side effects have been reported in cases of overdose, but symptomatic treatment may be provided if symptoms appear. This medication should only be given by intramuscular injection; other administration methods are not recommended.

Serious side effects

Cholestatic jaundice

Mild side effects

• Destructive bleeding, spotting, changes in menstrual flow, amenorrhea, cervical erosion, and changes in cervical mucus
• Breast changes, nipple edema
• Rash
• Liver spots, acanthosis nigricans, itching, acne, hair loss, hirsutism
• Elevated AST, ALT levels
• Nausea, vomiting, diarrhea
• Depression, insomnia, drowsiness, fever, migraine, headache, dizziness, fatigue
• Partial or complete vision loss, double vision, retinal vascular lesions
• Local reactions (pain, redness,

This medication is sensitive to light, so it should be stored in a light-protected, closed container. It is recommended to maintain a storage temperature between 15 to 30 degrees Celsius. Proper storage will help retain the medication's effectiveness for a longer period.

Appearance

A colorless to pale yellow clear oily solution in a glass vial

Package unit

10 vials/box [10ml/vial]